BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity

Blood

Volumn 125, Issue 8, 2015, Pages 1207-1216

  Pettirossi, Valentina ^a   Santi, Alessia ^a   Imperi, Elisa ^a   Russo, Guido ^a   Pucciarini, Alessandra ^a   Bigerna, Barbara ^a   Schiavoni, Gianluca ^a   Fortini, Elisabetta ^a   Spanhol Rosseto, Ariele ^a   Sportoletti, Paolo ^a   Mannucci, Roberta ^a   Martelli, Maria Paola ^a   Klein Hitpass, Ludger ^b   Falini, Brunangelo ^a   Tiacci, Enrico ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANTILEUKEMIC AGENT; B RAF KINASE; CYCLIN D1; DABRAFENIB; INTERLEUKIN 2 RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PURINE DERIVATIVE; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; SULFONAMIDE; TRANSCRIPTOME;

ANTILEUKEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW STROMA CELL; CANCER CHEMOTHERAPY; CELL STRUCTURE; CELL VIABILITY; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; GENE EXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HAIRY CELL LEUKEMIA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMIA RELAPSE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, HAIRY CELL; METABOLISM; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHOSPHORYLATION; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMIDAZOLES; INDOLES; LEUKEMIA, HAIRY CELL; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; OXIMES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SULFONAMIDES; TRANSCRIPTOME; TUMOR CELLS, CULTURED;

EID: 84923381003     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-10-603100     Document Type: Article

References (31)

1. Foucar MK, Falini B, Catovsky D, Stein H. In: Swerdlow SH, Campo E, Harris NL, et al, eds. Hairy Cell Leukemia in WHO Classification of Tumours of Haemapoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008: 188-190.
2. Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet. 2004;363(9424):1869-1870.
3. Basso K, Liso A, Tiacci E, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med. 2004;199(1):59-68.
4. Tiacci E, Liso A, Piris M, Falini B. Evolving concepts in the pathogenesis of hairy-cell leukaemia. Nat Rev Cancer. 2006;6(6):437-448.
5. Kitagawa Y, Brahmachary M, Tiacci E, Dalla-Favera R, Falini B, Basso K. A microRNA signature specific for hairy cell leukemia and associated with modulation of the MAPK-JNK pathways. Leukemia. 2012;26(12):2564-2567.
6. Grever MR. How I treat hairy cell leukemia. Blood. 2010;115(1):21-28.
7. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145(6):733-740.
8. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305-2315.
9. Tiacci E, Schiavoni G, Forconi F, et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood. 2012;119(1):192-195.
10. Arcaini L, Zibellini S, Boveri E, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood. 2012;119(1):188-191.
11. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
12. Keshet Y, Seger R. The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol. 2010;661:3-38.
13. Tiacci E, Schiavoni G, Martelli MP, et al. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica. 2013;98(4):635-639.
14. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
15. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-365.
16. Flaherty KT, Robert C, Hersey P, et al; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-114.
17. Tiacci E, Pucciarini A, Bigerna B, et al. Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia. Blood. 2012;119(22):5332-5333.
18. Weston-Bell NJ, Hendriks D, Sugiyarto G, et al. Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins. Leukemia. 2013;27(1):241-245.
19. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550.
20. Pratilas CA, Taylor BS, Ye Q, et al. (V600E) BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA. 2009;106(11):4519-4524.
21. Yam LT, Li CY, Lam KW. Tartrate-resistant acid phosphatase isoenzyme in the reticulum cells of leukemic reticuloendotheliosis. N Engl J Med. 1971;284(7):357-360.
22. Miranda RN, Briggs RC, Kinney MC, Veno PA, Hammer RD, Cousar JB. Immunohistochemical detection of cyclin D1 using optimized conditions is highly specific for mantle cell lymphoma and hairy cell leukemia. Mod Pathol. 2000;13(12):1308-1314.
23. Raghunathan A, Sivakamasundari R, Wolenski J, Poddar R, Weissman SM. Functional analysis of B144/LST1: a gene in the tumor necrosis factor cluster that induces formation of long filopodia in eukaryotic cells. Exp Cell Res. 2001;268(2):230-244.
24. Schiller C, Diakopoulos KN, Rohwedder I, et al. LST1 promotes the assembly of a molecular machinery responsible for tunneling nanotube formation. J Cell Sci. 2013;126(Pt 3):767-777.
25. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA. 2008;105(8):3041-3046.
26. Chilosi M, Chiarle R, Lestani M, et al. Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia. Br J Haematol. 2000;111(1):263-271.
27. Vlachos P, Nyman U, Hajji N, Joseph B. The cell cycle inhibitor p57 (Kip2) promotes cell death via the mitochondrial apoptotic pathway. Cell Death Differ. 2007;14(8):1497-1507.
28. Pardanani A, Tefferi A. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;365(10):961-962.
29. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14(7):455-467.
30. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135-2147.
31. Sári E, Nagy ZG, Baghy K, et al. Treatment of refractory hairy cell leukemia with a BRAFinhibitor: lessons to be learnt. Pathol Oncol Res. 2014;20(4):973-980.